Holen Sie sich die Stockscreener-App
16.10
0.50%
0.08
Handel nachbörslich:
16.09
-0.01
-0.06%
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Zacks Investment Research
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen - marketbeat.com
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH - marketbeat.com
Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares - stocktitan.net
Theravance Biopharma (TBPH) CFO receives 37,500-share equity grant in Form 4 - stocktitan.net
Theravance Biopharma (TBPH) SVP receives 37,500-share equity grant - stocktitan.net
Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing - stocktitan.net
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - businesswire.com
TBPH PE Ratio & Valuation, Is TBPH Overvalued - Intellectia AI
How Theravance Biopharma Inc. (TBPH) Affects Rotational Strategy Timing - Stock Traders Daily
Tudor Investment Corp ET AL Decreases Stake in Theravance Biopharma, Inc. $TBPH - marketbeat.com
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Big Picture: Can Theravance Biopharma Inc sustain its profitabilityLayoff News & Daily Profit Focused Screening - baoquankhu1.vn
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement - TipRanks
Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission. - Bitget
Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement - stocktitan.net
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen - marketbeat.com
Theravance Biopharma SEC Filing: Exhibits, Documents, and XBRL Taxonomy Reference Table - Minichart
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49 - MSN
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP - GlobeNewswire
Theravance's Q4 earnings and revenues miss estimates - msn.com
Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake - Stock Titan
Theravance drops rare disease drug after late-stage trial setback - MSN
Theravance Biopharma (NASDAQ:TBPH) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
TBPH: Today's Rating Maintained by TD Cowen with Raised Price Ta - GuruFocus
TD Cowen raises Theravance Biopharma stock price target on cash flow focus - Investing.com Canada
Theravance Biopharma 2025 Annual Report: YUPELRI Commercialization, Strategic Review, and Organizational Restructuring - Minichart
Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income - tradingview.com
Theravance Biopharma (NASDAQ: TBPH) restructures after ampreloxetine flop and royalty sale - Stock Titan
Here's why Theravance Biopharma (TBPH) is a strong growth stock - MSN
(TBPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Lowered by Wall Street Zen - marketbeat.com
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
BTIG Research Reaffirms "Buy" Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock - Yahoo Finance
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $0.71 EPS - MarketBeat
Theravance Biopharma (TBPH) Profit Swing Reinforces Bullish Narratives Despite Narrow Revenue Base - simplywall.st
Theravance Biopharma stock rating reiterated at Buy by BTIG on revenue beat - Investing.com Canada
Theravance Biopharma earnings beat by $0.15, revenue fell short of estimates - Investing.com Canada
Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN
Theravance Biopharma Q4 operating income USD 20.012 million - marketscreener.com
Theravance Biopharma 2025 Earnings: Q4 Profit $61M, Revenue Misses EstimatesNews and Statistics - IndexBox
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Theravance Biopharma (TBPH) Achieves Record Quarter Amidst Strat - GuruFocus
BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million - TradingView
Ireland's Theravance Biopharma Q4 revenue misses expectations - TradingView
Theravance Biopharma reports Q4 2025 net income $61.0M; Q4 revenue $45.9M, cash ~ $400M expected Q1 2026 - TradingView
Theravance Bio: Q4 Earnings Snapshot - kare11.com
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PR Newswire
Theravance Biopharma SVP Farnum sells $433k in shares By Investing.com - Investing.com India
Insider Sell: Rhonda Farnum Sells Shares of Theravance Biopharma Inc (TBPH) - GuruFocus
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):